NOTICE OF PERFORMANCE SHARES AWARD

VOLITIONRX LIMITED

2026 STOCK INCENTIVE PLAN

Unless otherwise defined herein, the terms defined in the VolitionRx Limited (the “Company”) 2026 Stock Incentive Plan (the “Plan”) shall have the same meanings in this Notice of Performance Shares Award (the “Notice”) and the attached Performance Shares Award Agreement (the “Performance Shares Agreement”).  You have been granted an award of Performance Shares (the “Performance Shares Award”) under the Plan subject to the terms and conditions of the Plan, this Notice and the attached Performance Shares Agreement.

Name: *                                                                                    *

…

**  EXHIBIT 10.7**

NOTICE OF STOCK OPTION GRANT

**VOLITIONRX LIMITED **2026 STOCK INCENTIVE PLAN

Unless otherwise defined herein, the terms defined in the VolitionRx Limited (the “Company”) 2026 Stock Incentive Plan (the “Plan”) shall have the same meanings in this Notice of Stock Option Grant (the “Notice of Grant”) and the attached Stock Option Agreement (the “Option Agreement”). You have been granted an Option to purchase shares of Common Stock of the Company under the Plan subject to the terms and conditions of the Plan, this Notice of Grant and the attached Option Agreement.

| | |

…

NOTICE OF STOCK APPRECIATION RIGHT AWARD

VOLITIONRX LIMITED

2026 STOCK INCENTIVE PLAN

Unless otherwise defined herein, the terms defined in the VolitionRx Limited (the “Company”) 2026 Stock Incentive Plan (the “Plan”) shall have the same meanings in this Notice of Stock Appreciation Right Award (the “Notice of Grant”) and the attached Stock Appreciation Right Agreement (the “SAR Agreement”). You have been granted an award of Stock Appreciation Rights (the “SAR”) of the Company under the Plan subject to the terms and conditions of the Plan, this Notice of Grant and the SAR Agreement.

| | |

…

NOTICE OF RESTRICTED STOCK UNIT AWARD

VOLITIONRX LIMITED

2026 STOCK INCENTIVE PLAN

Unless otherwise defined herein, the terms defined in the VolitionRx Limited (the “Company”) 2026 Stock Incentive Plan (the “Plan”) shall have the same meanings in this Notice of Restricted Stock Unit Award (the “Notice”) and the attached Restricted Stock Unit Agreement (the “RSU Agreement”). You have been granted an award of Restricted Stock Units (“RSUs”) under the Plan subject to the terms and conditions of the Plan, this Notice and the attached RSU Agreement.

Name: ____________________________

…

**  EXHIBIT 10.4**

NOTICE OF RESTRICTED STOCK AWARD

VOLITIONRX LIMITED

2026 STOCK INCENTIVE PLAN

Unless otherwise defined herein, the terms defined in the VolitionRx Limited (the “Company”) 2026 Stock Incentive Plan (the “Plan”) shall have the same meanings in this Notice of Restricted Stock Award (the “Notice”) and the attached Restricted Stock Agreement (the “Restricted Stock Agreement”). You have been granted the opportunity to purchase Shares of the Company that are subject to restrictions (the “Restricted Shares”) and the terms and conditions of the Plan, this Notice and the attached Restricted Stock Agreement.

| |

…

VOLITIONRX LIMITED

2026 STOCK INCENTIVE PLAN

As adopted by the Board of Directors on May 11, 2026

ARTICLE 1

PURPOSES OF THE PLAN

1.1 Purposes. The purposes of the Plan are (a) to enhance the Company’s ability to attract and retain the services of qualified employees, officers, directors, consultants and other service providers upon whose judgment, initiative and efforts the successful conduct and development of the Company’s business largely depends and (b) to provide additional incentives to such persons or entities to devote their utmost effort and skill to the advancement and betterment of the Company, by providing them an opportunity to participate in the ownership of the Company and thereby have an interest in the success and increased value of the Company.

ARTICLE 2

DEFINITIONS

For purposes of this Plan, terms not otherwise defined herein will have the meanings indicated below:

**2.1 *“Affiliate” ***means (i) any entity that, directly or indirectly, is controlled by, controls or is under common control with, the Company and (ii) any entity in which the Company has a significant equity interest, in either case as determined by the Committee, whether now or hereafter existing.

**2.2 *“Award” ***means any award under the Plan, including any Option, Restricted Stock, Stock Bonus, Stock Appreciation Right, Restricted Stock Unit or Performance Awards.

…

WAIVER AND CONSENT

This Waiver AND CONSENT (this “Waiver and Consent”) is dated as of May 21, 2026, by and between VolitionRx Limited, a Delaware corporation (the “Company” or “Maker”), and Lind Global Asset Management XII LLC, a Delaware limited liability company (“Lind” or “Holder”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Notes (defined below). The terms of this Waiver and Consent shall be deemed effective as of May 8, 2026 (the “Effective Date”).

WHEREAS, the Company and Lind previously entered into a Securities Purchase Agreement, dated May 15, 2025, as amended and restated on January 7, 2026 (the “A&R Purchase Agreement”), pursuant to which the Company issued and sold to Lind in private placement transactions in addition to certain common stock purchase warrants, (a) a senior secured convertible promissory note in the principal amount of $7,500,000 (the “May Note”) that is convertible into shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (b) a senior secured convertible promissory note in the principal amount of $2,400,000 (together with the May Note, the “Notes”);

WHEREAS, Section 2.1(s) of each Note provides that an Event of Default occurs if the Company’s Market Capitalization is below $22,500,000 for ten consecutive Trading Days (a “Market Capitalization Default”);

WHEREAS, a Market Capitalization Default occurred as of the Effective Date; and

…

August 12, 2026

Justin Trojanowski

Re: Further Amended & Restated Tempest Employment Terms

Dear Justin,

You are currently employed byTempest Therapeutics, Inc. ("Tempest" or the "Company") pursuant to the terms of the offer letter you entered into with the Company on May 19, 2022, which was first amended and restated via the Tempest Employment Terms letter agreement on August 8, 2025 (collectively, the “Offer Letter”). The terms and conditions set forth in this letter agreement (this “Amended Offer Letter”) shall become effective as of the date hereof and shall supersede and replace the terms and conditions set forth in the Offer Letter.

As of June 4, 2026, you have been appointed as the Company’s Vice President, Finance, Principal Financial Officer, and Corporate Secretary. You will also continue to hold the designation of Corporate Controller and Treasurer and Principal Accounting Officer. In such roles, you are responsible for overseeing the Company’s finance, accounting and treasury functions, including maintaining the Company’s internal control framework in accordance with Sarbanes-Oxley, supporting the preparation and review of quarterly and annual financial statements, overseeing finance, accounting and treasury operations, supporting budgeting and forecasting processes, as well as performing such duties as are prescribed in the By-laws of the Company, as amended, and as assigned to you from time to time. Additionally, you will perform such duties and have such powers as are incident to the office of the secretary, as are prescribed in the By-laws of the

…

Tempest Therapeutics, Inc.

Non-Employee Director Compensation Policy

Each member of the Board of Directors (the “Board”) of Tempest Therapeutics, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Non-Employee Director”) will be eligible to receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for his or her Board service from the date hereof (the “Effective Date”). Unless otherwise defined herein, capitalized terms used in this Policy will have the meaning given to such terms in the Company’s Amended and Restated 2023 Equity Incentive Plan, as may be amended from time to time, or any successor equity incentive plan (the “Plan”).

This Policy may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board.

•

Annual Cash Compensation

Each Non-Employee Director will be entitled to receive the following annual cash retainers for service on the Board:

Annual Board Service Retainer:

•

All Non-Employee Directors: $20,000

•

Non-Executive Chairperson (additional retainer): $17,500

Annual Committee Chair Service Retainer (in lieu of Committee Member Service Retainer):

•

Chairperson of the Audit Committee: $10,000

•

Chairperson of the Compensation Committee: $7,500

•

Chairperson of the Nominating and Corporate Governance Committee: $5,000

•

Chairperson of the Science and Technology Committee: $6,000

Annual Committee Member Service Retainer:

•

Member of the Audit Committee: $5,000

•

…

June 4, 2026 (Revised June 19, 2026)

Nicholas Maestas

Re: Separation Agreement and General Release

Dear Nic:

This letter confirms that you tendered your notice of resignation from Tempest Therapeutics, Inc. (the “Company”) effective June 5, 2026 and your employment ended on that date (the “Separation Date”). This letter sets forth the substance of the separation agreement and general release (the “Agreement”) that the Company is offering to you.

1. Accrued Benefits; Cessation of Equity Vesting.Regardless of whether this Agreement becomes effective, (a) the Company will pay you the Accrued Benefits (as defined under Section 4(a)(i) of your February 3, 2026 Employment Agreement (the “Employment Agreement”)); (b) your participation in the Company’s group health plans will cease on the last day of the month in which the Separation Date occurs and you will be provided with a separate notice describing your rights and obligations under COBRA and a form for electing COBRA coverage; and (c) any outstanding equity awards you have received from the Company will cease vesting on the Separation Date, with the unvested portion being forfeited and the vested portion remaining subject to the terms and conditions of the applicable grant notices, award agreements, and governing plan documents.

…

SEPARATION AGREEMENT

May 23, 2026

This Separation Agreement (this “Agreement”) is made on the date first written above by and between Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), and Ronit Simantov (the “Director”).

In consideration of the mutual covenants set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1.

Separation Date. The Director hereby resigns from the Company’s Board of Directors and all committees thereof effective as of May 23, 2026 (the “Separation Date”).

2.

Director Compensation. The Director hereby waives all rights to any accrued and unpaid director compensation. Nothing in this Agreement shall affect the Director’s rights under the Director’s outstanding stock option awards or the Director’s ownership of shares of capital stock of the Company, subject to the terms of the applicable award agreement between the Director and the Company and the terms of the Company’s Amended and Restated 2019 Equity Incentive Plan.

3.

…

SEPARATION AGREEMENT

May 22, 2026

This Separation Agreement (this “Agreement”) is made on the date first written above by and between Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), and Michael Raab (the “Director”).

In consideration of the mutual covenants set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1.

Separation Date. The Director hereby resigns from the Company’s Board of Directors and all committees thereof effective as of May 22, 2026 (the “Separation Date”).

2.

Director Compensation. The Director hereby waives all rights to any accrued and unpaid director compensation. Nothing in this Agreement shall affect the Director’s rights under the Director’s outstanding stock option awards or the Director’s ownership of shares of capital stock of the Company, subject to the terms of the applicable award agreement between the Director and the Company and the terms of the Company’s Amended and Restated 2019 Equity Incentive Plan.

3.

…